A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice
July 5th, 2024
This protocol introduces a technique for inducing polycystic ovary syndrome (PCOS) models in mice through controlled letrozole release using mini-pumps. Under adequate anesthesia, the mini-pump was implanted subcutaneously, and PCOS was successfully induced in the mice after a certain period of the mini-pump release.
Our research focuses primarily on the physiological and the pathological mechanisms related to Polycystic Ovary Syndrome. Specifically, this research aims to develop a simple and efficient technique in inducing PCOS in mouse in order to better simulate and study the physiological policies of PCOS, P-C-O-S. In 2023, academician team published a study in circulation that proposed a new mechanism involving chronic inflammation in the development of high-risk cardiovascular disease in patients with Polycystic Ovary Syndrome.
Our protocol offers time-saving and flexible method to effectfully induce PCOS in mice, avoid repeated drug administration, and reduces the influence of non-experimental factors. Our laboratory will focus on investigating the mechanism behind the developmental origins of disease. We aim to uncover how adverse early-life exposure contribute to the onset of metabolic, cardiovascular, and neurological disorders later in life.
To begin, place mini pumps on a clean, sterile countertop. With the thumb and forefinger, gently pinch the cap that matches the pump body and hold the pump body with the other hand. Use the thin tube attached to the cap to poke the filling port of the pump several times.
Now, take a needle that matches the pump and the one-milliliter syringe. Attach the needle to the syringe tightly. Slowly draw out the final solution of Letrozole into the syringe.
Next, carefully pinch a mini pump with one hand so that it stands upright. With the other hand, insert the one-milliliter syringe into the bottom of the pump. Slowly inject the Letrozole solution into the pump.
When the pump is full, withdraw the syringe. Carefully, insert the cap into the pump body and tighten it. Wipe away any spillage that occurs.
With the outlet of the filled pump facing outwards, immerse the pump into sterile saline in a prepared centrifuge tube. Cap the tube and place it on the tube rack. Place the tubes in a thermostat at 37 degrees Celsius for 48 hours.
To begin, secure an anesthetized mouse in the prone position on an operating plate. Use forceps to pick up the skin at the midline of the back of the neck, favoring the skin on the hairless side. With a scalpel, laterally make a 0.5-centimeter-long incision.
Then, open the epidermis underneath the incision and access it with a hemostat to free the skin, making room for a mini pump. Next, use sterile forceps to take a Letrozole-filled mini pump out of the saline with the open end of the pump facing downward. With a pair of forceps, clamp up one side of the skin incision.
Then, push the pump into the subcutaneous space. Once the pump is inside, use your fingers to gently squeeze the pump as inward as possible. Then, use 4-0 surgical sutures to suture the incision site.
The Letrozole mini pump-treated mice exhibited significantly elevated serum testosterone levels relative to the female control mice. Histological analysis of the mice ovaries showed that the treated mice had a significant reduction in the corpora lutea number. They also showed significant estrous acyclicity and were heavier than the control mice.
The treated mice developed glucose intolerance and had higher changes in serum lipid profiles.
Overview
This protocol introduces a technique for inducing polycystic ovary syndrome (PCOS) models in mice through controlled letrozole release using mini-pumps. This method allows for a more accurate simulation of PCOS, facilitating the study of its physiological mechanisms.
Key Study Components
Area of Science
- Neuroscience
- Endocrinology
- Physiology
Background
- Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder.
- Chronic inflammation has been linked to cardiovascular disease in PCOS patients.
- Understanding PCOS mechanisms can help in developing targeted therapies.
- Mouse models are essential for studying the disease's pathophysiology.
Purpose of Study
- To develop an efficient technique for inducing PCOS in mice.
- To simulate the physiological aspects of PCOS accurately.
- To investigate the developmental origins of metabolic and cardiovascular disorders.
Methods Used
- Controlled release of letrozole using mini-pumps.
- Subcutaneous implantation of mini-pumps under anesthesia.
- Monitoring of physiological changes in mice post-induction.
- Analysis of the impact of early-life exposure on disease development.
Main Results
- Successful induction of PCOS in mice using the mini-pump method.
- Reduction in the need for repeated drug administration.
- Minimized influence of non-experimental factors on results.
- Facilitated further research into the mechanisms of PCOS.
Conclusions
- The mini-pump technique is an effective method for inducing PCOS in mice.
- This model can enhance understanding of PCOS-related disorders.
- Future studies can build on this method to explore long-term health impacts.
Frequently Asked Questions
Executive Industry Relevance
Robust animal models are essential for elucidating the mechanisms underlying polycystic ovary syndrome (PCOS) and for preclinical evaluation of therapeutic candidates. The described mini-pump letrozole delivery system enables reproducible induction of PCOS phenotypes in mice, supporting translational research and mechanistic de-risking at early discovery stages. This approach streamlines model generation, reduces confounding variables, and enhances predictive confidence for downstream R&D decisions.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of PCOS pathophysiology and mechanistic pathways in a controlled in vivo system.
- Supports biological de-risking by replicating metabolic and reproductive phenotypes relevant to human disease.
- Facilitates functional target validation for candidate interventions in a disease-relevant context.
Screening & Assay Development
- Provides a standardized, reproducible model for evaluating pharmacological effects on PCOS-related endpoints.
- Reduces variability and stress-induced artifacts by eliminating daily dosing regimens.
- Enables quantitative assessment of serum biomarkers, metabolic parameters, and reproductive outcomes.
Translational & Preclinical Research
- Aligns preclinical model outputs with clinical PCOS features, supporting translational biomarker development.
- Enables investigation of developmental origins and comorbidities such as metabolic and cardiovascular dysfunction.
- Supports risk-adjusted advancement of therapeutic hypotheses into later-stage validation.
Pipeline & Workflow Integration
This mini-pump model integrates into the discovery-to-preclinical continuum, providing a foundation for target validation, lead identification, and translational research in PCOS and related metabolic disorders.
- Discovery Biology: Facilitates hypothesis testing on PCOS mechanisms and pathway involvement.
- Screening: Delivers assay-ready, reproducible in vivo systems for compound evaluation.
- Analytics: Enables quantitative measurement of hormonal, metabolic, and histological endpoints.
- Translational Research: Bridges discovery findings to preclinical biomarker and comorbidity studies.
- Enterprise Reuse: Offers a scalable, standardized model adaptable across research teams and programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in PCOS research.
- Operational Value: Streamlines model induction, minimizes animal stress, and enhances reproducibility.
- Strategic Value: Improves go/no-go decision quality and capital efficiency in early-stage programs.
- Portfolio Impact: Supports risk-adjusted prioritization and cross-program model standardization.
Implementation Considerations
- Requires expertise in surgical mini-pump implantation and animal handling.
- Needs access to standard laboratory instrumentation and validated letrozole formulations.
- Demands cross-team alignment on model induction protocols and endpoint measurements.
- Adaptable to various mouse strains but may require optimization for specific research questions.
- Potential limitations include model-specific phenotypic variability and translational scope.
